Spots Global Cancer Trial Database for fallopian tube neoplasms
Every month we try and update this database with for fallopian tube neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pharmacogenomics of Paclitaxel in Ovarian Cancer | NCT00415207 | Ovarian Neoplas... Fallopian Tube ... | 18 Years - | University of Southern Denmark | ||
| Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | NCT03976999 | Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop... | Biological coll... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients | NCT02444195 | Uterine Cervica... Uterine Neoplas... Ovarian Neoplas... Urogenital Neop... Fallopian Tube ... | Guided Imagery ... | 18 Years - | University of Michigan | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| DNA Single Nucleotide Polymorphisms as Predictors of Toxicity | NCT02478476 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | 18 Years - | OvaGene Oncology, Inc. | ||
| Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | NCT00074867 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | CP-547,632 | 18 Years - | Pfizer | |
| Developing a Test for the Detection of Ovarian Cancer | NCT04794322 | Ovarian Neoplas... Ovarian Epithel... Fallopian Tube ... High Grade Ovar... Stage I Ovarian... Stage II Ovaria... Stage III Ovari... Stage IIIA Ovar... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari... | Uterine lavage,... Blood sample Pap smear | 30 Years - | Massachusetts General Hospital | |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | NCT03593681 | Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease... | Hysteroscopic c... | 18 Years - | Boston Scientific Corporation | |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT01932125 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | NCT00191646 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | NCT00112086 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Neoadjuvant che... | 20 Years - 75 Years | Japan Clinical Oncology Group | |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | NCT00035100 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | epothilone b | 18 Years - | Novartis | |
| Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | NCT01313078 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Pegylated L-Asp... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | NCT04498117 | Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop... | Oregovomab Paclitaxel Carboplatin Placebo Carboplatin | 18 Years - | CanariaBio Inc. | |
| Developing a Test for the Detection of Ovarian Cancer | NCT04794322 | Ovarian Neoplas... Ovarian Epithel... Fallopian Tube ... High Grade Ovar... Stage I Ovarian... Stage II Ovaria... Stage III Ovari... Stage IIIA Ovar... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari... | Uterine lavage,... Blood sample Pap smear | 30 Years - | Massachusetts General Hospital | |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | NCT00443196 | Adenocarcinoma Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | MiCK Assay | - | Pierian Biosciences | |
| A Prospective Trial of COXEN Chemotherapy Prediction | NCT01228942 | Ovarian Neoplas... Fallopian Tube ... | COXEN analysis ... | 18 Years - 95 Years | University of Virginia | |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | NCT00443196 | Adenocarcinoma Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | MiCK Assay | - | Pierian Biosciences | |
| Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients | NCT02444195 | Uterine Cervica... Uterine Neoplas... Ovarian Neoplas... Urogenital Neop... Fallopian Tube ... | Guided Imagery ... | 18 Years - | University of Michigan | |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) | NCT04111978 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... High-grade Sero... Low-grade Serou... Ovarian Endomet... | Letrozole 2.5mg Placebo | 18 Years - | Swiss GO Trial Group | |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | NCT01932125 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers | NCT03976999 | Carcinoma, Ovar... Fallopian Tube ... Peritoneal Neop... | Biological coll... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | NCT01610869 | Ovarian Cancer Fallopian Tube ... | BIBF 1120 | 18 Years - | University College, London | |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | NCT03648489 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton... | Paclitaxel TAK228 | 18 Years - | Imperial College London | |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00063401 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Cetuximab: Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | NCT01681368 | Epithelial Ovar... Peritoneal Neop... Fallopian Tube ... | Birinapant (TL3... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | NCT00191646 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | NCT01610869 | Ovarian Cancer Fallopian Tube ... | BIBF 1120 | 18 Years - | University College, London | |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors | NCT04196257 | Solid Tumor, Ad... Carcinoma, Ovar... Fallopian Tube ... Endometrial Can... Peritoneal Canc... Solid Tumor | BP1001-A (Lipos... BP1001-A (Lipos... | 18 Years - | Bio-Path Holdings, Inc. | |
| A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer | NCT01654458 | Sexual Dysfunct... Uterine Cervica... Ovarian Neoplas... Uterine Neoplas... Genital Neoplas... | GyneGals Suppor... | 18 Years - | Women's College Hospital | |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | NCT00191646 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine Paclitaxel Carboplatin | 18 Years - | Eli Lilly and Company | |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | NCT01462890 | Genital Disease... Ovarian Disease... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Bevacizumab Paclitaxel Carboplatin specialized pat... | 18 Years - | AGO Study Group | |
| Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | NCT01279291 | Neoplasms Ovarian Neoplas... Fallopian Tube ... Primary Periton... | KHK2866 Gemcitabine and... paclitaxel pegylated lipos... | 18 Years - | Kyowa Kirin Co., Ltd. | |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | NCT03000192 | Breast Cancer F... Breast Neoplasm Non-Hodgkin's B... Non-Hodgkin's L... NonHodgkin Lymp... Diffuse Large B... Diffuse Large C... Ovarian Cancer Ovarian Neoplas... Endometrial Can... Endometrial Neo... Cervical Cancer Cervical Neopla... Primary Periton... Fallopian Tube ... Fallopian Tube ... Vulvar Cancer Vulvar Neoplasm... | 16 Years - | University Hospital Southampton NHS Foundation Trust | ||
| MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer | NCT05960630 | Ovarian Cancer Ovarian Neoplas... Ovarian Neoplas... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... | MIRRORS Protoco... Standard Open C... | 18 Years - | Royal Surrey County Hospital NHS Foundation Trust | |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | NCT05116189 | Ovarian Cancer Carcinoma, Ovar... Fallopian Tube ... | Pembrolizumab Paclitaxel Bevacizumab Placebo for pem... Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. | NCT02903771 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Part A: Dose Es... Part B: Expansi... | 18 Years - | Kazia Therapeutics Limited | |
| Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | NCT00103545 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | ACA 125 | 0 Years - | AGO Study Group | |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | NCT00407407 | Fallopian Tube ... Peritoneal Neop... Ovarian Neoplas... | ABI-007 Carboplatin | 18 Years - | Celgene | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | NCT00698451 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | doxorubicin HCL... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer | NCT00415181 | Ovarian Neoplas... Fallopian Tube ... | 18 Years - | University of Southern Denmark | ||
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer | NCT01610869 | Ovarian Cancer Fallopian Tube ... | BIBF 1120 | 18 Years - | University College, London | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | NCT03648489 | Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Ovarian Serous ... Ovarian Endomet... Ovarian Clear C... Fallopian Tube ... Fallopian Tube ... Primary Periton... Primary Periton... | Paclitaxel TAK228 | 18 Years - | Imperial College London | |
| MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer | NCT05960630 | Ovarian Cancer Ovarian Neoplas... Ovarian Neoplas... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... | MIRRORS Protoco... Standard Open C... | 18 Years - | Royal Surrey County Hospital NHS Foundation Trust | |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | NCT00326885 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | NCT00391118 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | enzastaurin carboplatin paclitaxel placebo | 18 Years - | Eli Lilly and Company | |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | NCT05116189 | Ovarian Cancer Carcinoma, Ovar... Fallopian Tube ... | Pembrolizumab Paclitaxel Bevacizumab Placebo for pem... Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | NCT03593681 | Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease... | Hysteroscopic c... | 18 Years - | Boston Scientific Corporation | |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | NCT01478685 | Urinary Bladder... Carcinoma, Tran... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... Carcinoma, Non-... Carcinoma, Panc... Tumor Virus Inf... | CC-486 Carboplatin ABI-007 | 18 Years - | Celgene | |
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | NCT00191607 | Genital Neoplas... Fallopian Tube ... Ovarian Neoplas... Pelvic Neoplasm... Peritoneal Neop... | Gemcitabine liposomal doxor... | 18 Years - | Eli Lilly and Company | |
| Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | NCT00189345 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | anti-EpCAM x an... | 18 Years - | AGO Study Group | |
| OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | NCT00112086 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Neoadjuvant che... | 20 Years - 75 Years | Japan Clinical Oncology Group | |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT01846611 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | Trabectedin DOXIL Dexamethasone DOXIL | 18 Years - | Janssen Research & Development, LLC | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | NCT01478685 | Urinary Bladder... Carcinoma, Tran... Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... Carcinoma, Non-... Carcinoma, Panc... Tumor Virus Inf... | CC-486 Carboplatin ABI-007 | 18 Years - | Celgene | |
| A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer | NCT01654458 | Sexual Dysfunct... Uterine Cervica... Ovarian Neoplas... Uterine Neoplas... Genital Neoplas... | GyneGals Suppor... | 18 Years - | Women's College Hospital | |
| Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | NCT00074867 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | CP-547,632 | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
